Pfizer and BioNTech are the primary drugmakers to point out profitable knowledge from a large-scale medical trial of a coronavirus vaccine. The firms mentioned they’ve to date discovered no critical security issues and anticipate to hunt U.S. emergency use authorization later this month.
From humble roots because the son of a Turkish immigrant working at a Ford manufacturing facility in Cologne, BioNTech Chief Executive Ugur Sahin, 55, now figures among the many 100 richest Germans, collectively along with his spouse and fellow board member Oezlem Tuereci, 53, in accordance with weekly Welt am Sonntag.
The market worth of Nasdaq-listed BioNTech, which the pair co-founded, had ballooned to $21 billion as of Friday’s shut from $4.6 billion a yr in the past, with the agency set to play a significant position in mass immunisation towards the coronavirus.
“Despite his achievements, he never changed from being incredibly humble and personable,” mentioned Matthias Kromayer, board member of enterprise capital agency MIG AG, whose funds have backed BioNTech since its inception in 2008.
He added Sahin would sometimes stroll into enterprise conferences sporting denims and carrying his signature bicycle helmet and backpack with him.
Doggedly pursuing his childhood dream of finding out drugs and turning into a doctor, Sahin labored at educating hospitals in Cologne and the southwestern metropolis of Homburg, the place he met Tuereci throughout his early educational profession.
Medical analysis and oncology grew to become a shared ardour.
Tuereci, the daughter of a Turkish doctor who had migrated to Germany, mentioned in a media interview that even on the day of their marriage ceremony, each made time for lab work.
Together they honed in on the immune system as a possible ally within the battle towards most cancers and tried to handle the distinctive genetic make-up of every tumour.
Life as entrepreneurs began in 2001 once they arrange Ganymed Pharmaceuticals to develop cancer-fighting antibodies, however Sahin – by then a professor at Mainz college – by no means gave up educational analysis and educating.
They received funding from MIG AG in addition to from Thomas and Andreas Struengmann, who bought their generic medicine enterprise Hexal to Novartis in 2005.
That enterprise was bought to Japan’s Astellas in 2016 for as much as $1.Four billion. By then, the crew behind Ganymed was already busy constructing BioNTech, based in 2008, to pursue a wider vary of most cancers immunotherapy instruments.
That included mRNA, a flexible messenger substance to ship genetic directions into cells.
For MIG’s Kromayer, Tuereci and Sahin are a “dream team” in that they reconciled their visions with the constraints of actuality.
The BioNTech story took a twist when Sahin in January got here throughout a scientific paper on a brand new coronavirus outbreak within the Chinese metropolis of Wuhan and it struck him how small the step was from anti-cancer mRNA medicine to mRNA-based viral vaccines.
BioNTech rapidly assigned about 500 employees to undertaking “light speed” to work on a number of doable compounds, successful pharma big Pfizer and Chinese drugmaker Fosun as companions in March.
Matthias Theobald, a fellow oncology professor at Mainz college who has labored with Sahin for 20 years, mentioned his tendency in direction of understatement belies a relentless ambition to rework drugs, exemplified by the leap of religion to a Covid-19 vaccine.
“He is a very modest and humble person. Appearances mean little to him. But he wants to create the structures that allow him to realise his visions and that’s where is aspirations are far from modest,” Theobald mentioned.
Sahin informed Reuters on Monday the read-out amounted to an “extraordinary success rate” however that he didn’t know earlier within the yr how tough the duty total can be.
“It’s certainly not something that you would easily voice as a serious scientist, but it was within the realms of possibility from the beginning.”